Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

DMXAA (Vadimezan), mSTING Agonist

DMXAA (Vadimezan), mSTING Agonist

$79.00
A potent and selective mSTING agonist, selective for mouse STING over human STING.
Catalog No. Unit Price Qty
M60301-2s 2 mg solid $79.00

Details

Product Information
Molecular Weight: 282.29
Formula: C17H14O4
Purity: ≥98%
CAS#: 117570-53-3
Solubility: DMSO up to 20 mM
Chemical Name: 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

DMXAA (Vadimezan) is a potent and selective mSTING agonist, selective for mouse STING over human STING. It induces IFN-β and cytokine production from bone marrow-derived dendritic cells. It can cause tumor regression following intratumoral administration in mouse tumor models. DMXAA induces an adaptive immune response to reduce systemic tumor growth and provides immunological memory against autologous tumor re-challenge.


How to Use:

In vitro: DMXAA was used at 10-20 µM final concentration in various assays.
In vivo: Single dose DMXAA by intratumoral (IT) administration at 500 µg to get antitumor efficacy.

Reference:

  • 1. Phillips RM, et al. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. (1999) Biochem Pharmacol. 58(2):303-10.
  • 2. Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. (2011) J Leukoc Biol. 89(3):351-7. 
  • 3. Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. (2015) Cell Rep. 11(7):1018-30. 


DMXAA_spec.pdf      
  

Products are for research use only. Not for human use.

Description

Details

Product Information
Molecular Weight: 282.29
Formula: C17H14O4
Purity: ≥98%
CAS#: 117570-53-3
Solubility: DMSO up to 20 mM
Chemical Name: 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

DMXAA (Vadimezan) is a potent and selective mSTING agonist, selective for mouse STING over human STING. It induces IFN-β and cytokine production from bone marrow-derived dendritic cells. It can cause tumor regression following intratumoral administration in mouse tumor models. DMXAA induces an adaptive immune response to reduce systemic tumor growth and provides immunological memory against autologous tumor re-challenge.


How to Use:

In vitro: DMXAA was used at 10-20 µM final concentration in various assays.
In vivo: Single dose DMXAA by intratumoral (IT) administration at 500 µg to get antitumor efficacy.

Reference:

  • 1. Phillips RM, et al. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. (1999) Biochem Pharmacol. 58(2):303-10.
  • 2. Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. (2011) J Leukoc Biol. 89(3):351-7. 
  • 3. Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. (2015) Cell Rep. 11(7):1018-30. 


DMXAA_spec.pdf      
  

Products are for research use only. Not for human use.

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: